Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33)

 

The purpose of this initiative is to harness genome or epigenome editing technologies to functionally validate and characterize genetic or epigenetic variants involved in substance use disorders.The purpose is also that the genetic resources generated will be made broadly available to the scientific community to probe more deeply into the neurobiological mechanisms involved in the function of a variant, gene, or pathway and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.

Deleted 09/25/2015 (Archived.) RFA-DA-16-004 Agency: Department of Health and Human Services
Office: National Institutes of Health Grant Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. 08/25/2015 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-004.html FBOWebmaster@OD.NIH.GOV $2,000,000.00